Oric Pharmaceuticals, Inc.
Customers
0
None disclosed
Suppliers
2
2 disclosed
Latest period
Dec 31, 2025
10-K filed 2026-02-23
Suppliers 2
Companies that disclose ORIC as a major customer, as a share of their own revenue. 2 active, 0 lapsed.
| Company | % of their revenue | Est. $ from ORIC | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| Mirati Therapeutics, Inc. Mirati Therapeutics, Inc. |
Named | — | FY 2025-12-31 | — | Active | 10-K 2026-02-23 |
In August 2020, the Company licensed from Mirati Therapeutics, Inc. development and commercialization rights to an allosteric inhibitor program directed towards the polycomb repressive complex 2 (PRC2) and in October 2020, the Company licensed from Voronoi Inc. development and commercialization rights to a brain-penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency against exon 20 mutations.As of December 31, 2025, the Company had an accumulated deficit of $692.2 million. | ||||||
| Voronoi Inc. Non-SEC Voronoi Inc. |
Named | — | FY 2025-12-31 | — | Active | 10-K 2026-02-23 |
In August 2020, the Company licensed from Mirati Therapeutics, Inc. development and commercialization rights to an allosteric inhibitor program directed towards the polycomb repressive complex 2 (PRC2) and in October 2020, the Company licensed from Voronoi Inc. development and commercialization rights to a brain-penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency against exon 20 mutations.As of December 31, 2025, the Company had an accumulated deficit of $692.2 million. | ||||||
Alerts are coming
Get an email when ORIC's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.